Wadsworth Center Staff to Serve on the Association of Public Health Laboratories’ Overdose Biosurveillance Task Force

Dr. Kurunthachalam Kannan from the Division of Environmental Health Sciences (DEHS) at the Wadsworth Center, has been invited to serve on the Overdose Biosurveillance Task Force (OBTF), an advisory group charged by the Association of Public Health Laboratories (APHL) Board of Directors to provide subject matter expertise and input into the creation, dissemination, and promotion of resources for public health laboratories developing and conducting overdose biosurveillance programs in response to the evolving overdose epidemic. 

The Wadsworth Center Develops and Validates a New Method for the Analysis of Drugs in Urine from Overdose Patients

Fatal drug poisoning (“overdose”) is a growing public health crisis in the United States. According to the United States National Vital Statistics System, 105,007 drug overdose deaths occurred in 2023. Whereas opioids (including prescription opioids, heroin, fentanyl and analogs) were the leading cause of overdose deaths, the pharmacological composition of drugs has evolved into a “polysubstance death” crisis.  

The Wadsworth Center’s Dr. Denise Kay Discusses Complexities of Cystic Fibrosis Genetic Analysis at the North American Cystic Fibrosis Conference

Dr. Denise Kay, Director of the New York State Newborn Screening Program at the Wadsworth Center, was invited to present at the 2025 North American Cystic Fibrosis Conference, held October 22–25 in Seattle, Washington.

Wadsworth Center’s Mycobacteriology Laboratory Provides Critical Testing for Texas Drug-Resistant Tuberculosis Case

The Wadsworth Center’s Mycobacteriology Laboratory was contacted by the Texas Department of State Health Services to perform drug susceptibility testing for a transplant recipient previously treated for pre-extensively drug-resistant (XDR) tuberculosis beginning in 2022. After nine months of therapy, the patient was initially deemed cured following a treatment regimen consisting of bedaquiline, pretomanid, and linezolid (BPaL)—currently the standard for managing multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB).

Recent Wadsworth Center Study Highlights Advancements in Detecting Trace Levels of Uranium and Plutonium in Drinking Water

The Safe Drinking Water Act sets stringent standards for the detection of radioactive contaminants in public water systems. A new study from the Wadsworth Center’s Nuclear Chemistry Laboratory explores how these requirements might be exceeded through improved analytical sensitivity.

Wadsworth Center’s Dr. Joseph Orsini Receives George Cunningham Visionary Award in Newborn Screening

Dr. Joseph Orsini, Deputy Director of the Newborn Screening Program at the Wadsworth Center, has been honored with the 2025 George Cunningham Visionary Award in Newborn Screening. This prestigious lifetime achievement award recognizes individuals working in U.S.

Wadsworth Center Showcases Its Continued Leadership in Advancing Newborn Screening Science and Practice

The Association of Public Health Laboratories (APHL) held its annual Newborn Screening Symposium from October 5–9 in Providence, Rhode Island, bringing together approximately 570 scientists and healthcare professionals from across the United States and around the world. The symposium addressed a broad range of topics critical to public health newborn screening systems, including enhanced biochemical and molecular screening technologies; methods for detecting new conditions; quality improvement initiatives; strateg